IL6R
Basic information
Region (hg38): 1:154405193-154469450
Links
Phenotypes
GenCC
Source:
- hyper-IgE recurrent infection syndrome 5, autosomal recessive (Strong), mode of inheritance: AR
- hyper-IgE recurrent infection syndrome 5, autosomal recessive (Limited), mode of inheritance: AR
- hyper-IgE recurrent infection syndrome 5, autosomal recessive (Moderate), mode of inheritance: AR
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Hyper-IgE recurrent infection syndrome 5, autosomal recessive | AR | Allergy/Immunology/Infectious | The condition can involve early-onset recurrent and sever inffections, and awareness may allow prophylaxis and early and aggressive treatment of infections | Allergy/Immunology/Infectious | 31235509 |
ClinVar
This is a list of variants' phenotypes submitted to
- not_provided (247 variants)
- not_specified (47 variants)
- IL6R-related_disorder (16 variants)
- Hyper-IgE_recurrent_infection_syndrome_5,_autosomal_recessive (7 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the IL6R gene is commonly pathogenic or not. These statistics are base on transcript: NM_000000565.4. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 82 | 91 | ||||
| missense | 118 | 125 | ||||
| nonsense | 1 | |||||
| start loss | 0 | |||||
| frameshift | 4 | |||||
| splice donor/acceptor (+/-2bp) | 1 | |||||
| Total | 0 | 0 | 127 | 88 | 7 |
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| IL6R | protein_coding | protein_coding | ENST00000368485 | 10 | 64258 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 0.0000317 | 0.988 | 125708 | 0 | 39 | 125747 | 0.000155 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 0.689 | 254 | 287 | 0.885 | 0.0000173 | 3017 |
| Missense in Polyphen | 51 | 72.546 | 0.703 | 813 | ||
| Synonymous | -0.196 | 128 | 125 | 1.02 | 0.00000849 | 971 |
| Loss of Function | 2.23 | 11 | 22.4 | 0.491 | 0.00000102 | 245 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.000412 | 0.000412 |
| Ashkenazi Jewish | 0.000397 | 0.000397 |
| East Asian | 0.000163 | 0.000163 |
| Finnish | 0.0000925 | 0.0000924 |
| European (Non-Finnish) | 0.000133 | 0.000132 |
| Middle Eastern | 0.000163 | 0.000163 |
| South Asian | 0.0000980 | 0.0000980 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal. Signal activation necessitate an association with IL6ST. Activation may lead to the regulation of the immune response, acute-phase reactions and hematopoiesis.;
- Pathway
- PI3K-Akt signaling pathway - Homo sapiens (human);Non-alcoholic fatty liver disease (NAFLD) - Homo sapiens (human);HIF-1 signaling pathway - Homo sapiens (human);Jak-STAT signaling pathway - Homo sapiens (human);Th17 cell differentiation - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Hematopoietic cell lineage - Homo sapiens (human);Cytokine-cytokine receptor interaction - Homo sapiens (human);JAK-STAT-Core;Differentiation Pathway;IL-6 signaling pathway;Hepatitis C and Hepatocellular Carcinoma;Focal Adhesion-PI3K-Akt-mTOR-signaling pathway;Interleukin-4 and 13 signaling;PI3K-Akt Signaling Pathway;Senescence and Autophagy in Cancer;Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways;Signal Transduction;Signaling by Interleukins;il 6 signaling pathway;role of erbb2 in signal transduction and oncology;Cytokine Signaling in Immune system;JAK STAT MolecularVariation 1;Immune System;MAPK1 (ERK2) activation;IL-6 signaling;RAF-independent MAPK1/3 activation;SHP2 signaling;JAK STAT MolecularVariation 2;MAPK1/MAPK3 signaling;MAPK family signaling cascades;JAK STAT pathway and regulation;IL6;MAPK3 (ERK1) activation;Interleukin-6 signaling;Interleukin-6 family signaling;IL6-mediated signaling events
(Consensus)
Recessive Scores
- pRec
- 0.707
Intolerance Scores
- loftool
- 0.530
- rvis_EVS
- -0.16
- rvis_percentile_EVS
- 42.16
Haploinsufficiency Scores
- pHI
- 0.120
- hipred
- Y
- hipred_score
- 0.542
- ghis
- 0.464
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.985
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Il6ra
- Phenotype
- endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); cellular phenotype; immune system phenotype; homeostasis/metabolism phenotype; liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; hematopoietic system phenotype;
Gene ontology
- Biological process
- hepatic immune response;monocyte chemotaxis;positive regulation of leukocyte chemotaxis;positive regulation of T-helper 1 type immune response;acute-phase response;positive regulation of cell population proliferation;regulation of signaling receptor activity;positive regulation of activation of Janus kinase activity;cytokine-mediated signaling pathway;endocrine pancreas development;positive regulation of chemokine production;positive regulation of interferon-gamma production;positive regulation of interleukin-6 production;positive regulation of natural killer cell activation;response to cytokine;positive regulation of activated T cell proliferation;positive regulation of tyrosine phosphorylation of STAT protein;positive regulation of osteoblast differentiation;positive regulation of smooth muscle cell proliferation;positive regulation of lymphocyte proliferation;positive regulation of peptidyl-tyrosine phosphorylation;defense response to Gram-negative bacterium;positive regulation of NK T cell activation;interleukin-6-mediated signaling pathway;ciliary neurotrophic factor-mediated signaling pathway;extrinsic apoptotic signaling pathway
- Cellular component
- extracellular region;plasma membrane;interleukin-6 receptor complex;external side of plasma membrane;basolateral plasma membrane;apical plasma membrane;receptor complex;interleukin-12 complex;ciliary neurotrophic factor receptor complex;interleukin-23 complex
- Molecular function
- cytokine receptor activity;ciliary neurotrophic factor receptor activity;interleukin-6 receptor activity;interleukin-6 receptor binding;interleukin-12 receptor binding;protein binding;growth factor activity;enzyme binding;cytokine binding;interleukin-6 binding;interleukin-12 alpha subunit binding;protein homodimerization activity;interleukin-23 receptor binding;ciliary neurotrophic factor binding